Next-generation Diagnostics Outlook, 2022

Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testing.

With the arrival of blood-based assays for chronic disease screening and next-generation molecular and point-of-care diagnostics for COVID-19-related testing, the global market grew 15.5% in 2021. Digital health solutions (patient portal + mobile app) facilitate a dramatic shift in care delivery from traditional to alternative sites, simplifying accessibility of diagnostic tests, and delivering an automated testing experience for labs to ensure rapid scalability. Patients have greater access control/faster turnaround time to results; providers can triage patients quickly through an efficient and connected workflow.

Download a preview of this research by filling out the form to the right.

Sign up for a complimentary Growth Pipeline Dialog™

A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled market intelligence, technology insights, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential. Talk to our experts today!

Download Preview